Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEM-iSMART Sub-protocol C: ruxolitinib + venetoclax for relapsed or refractory pediatric leukemia or lymphoma with IL-7R/JAK-STAT pathway alterations
NL-OMON61104Phase 2Not yet recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib and venetoclax in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Maximum tolerated dose and Best overall response rate. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
ruxolitinibvenetoclax
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NL-OMON61104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61104.